Takeda Vaccines

Takeda Vaccines is the global vaccine business unit of Takeda Pharmaceutical Company, dedicated to developing and delivering innovative vaccines to address high-burden infectious diseases. The company's flagship product is Qdenga, a tetravalent dengue vaccine approved in over 30 countries, including the European Union, United Kingdom, and Indonesia. Takeda's robust pipeline features candidates for norovirus, Zika virus, and hand, foot, and mouth disease, utilizing advanced technologies like virus-like particles and live-attenuated platforms. The division operates a global network of research and manufacturing facilities, including a dedicated vaccine production site in Singen, Germany. Through strategic collaborations with organizations like the Bill & Melinda Gates Foundation and various government agencies, Takeda Vaccines focuses on expanding global access to life-saving immunizations.